ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 6

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

, , ,

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recent Guideline Updates in the Frontline Management of CLL
    EP. 2: Tailoring Treatment Approaches for Fit vs Unfit CLL Patients
    EP. 3: Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients
    EP. 4: Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data
    EP. 5: Clinical Insights and Real-World Evidence
    Now Viewing
    EP. 6: Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines
    EP. 7: Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options
    EP. 8: Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies
    EP. 9: Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy
    EP. 10: Relapse After Venetoclax-Based Therapy: Early vs Late Management
    EP. 11: Progression on BTK Inhibitors: Treatment Options and Considerations
    EP. 12: Emerging Agents and Future Strategies in Relapsed/Refractory CLL
    EP. 13: Reflections and Future Directions in CLL Management

    Video content above is prompted by the following:

    • Briefly comment on the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates and highlight the underlying rationale and data supporting this approach.
    x